Ambrx To Present Phase I/II Clinical Data For Optimized, Long Acting ... - Medical News Today

by Hgh @ Sun, 23 Nov 2008 02:00:02 -0600
Ambrx Inc. announced the scheduled presentation of data from a Phase I/II clinical trial of ARX201, the company's long-acting human growth hormone (hGH) analogue developed in collaboration with Merck Serono, at the International Congress of ...
  • Recent posts